https://irmhs.com/index.php/irmhs/issue/feed International Research in Medical and Health Sciences 2020-11-08T12:12:59-05:00 Yogesh Kumar editor.irmhs@gmail.com Open Journal Systems https://irmhs.com/index.php/irmhs/article/view/41 Reflections on the Special Experiment in General Medicine of the Non-Specific Antiviral Drug, and Authorized as Antitussive, Cloperastine. Talking Advantage of the Opportunity to Study its Effects on Coronavirus Disease 2019 (Covid-19) 2020-10-25T06:13:21-04:00 Dr. Jose Luis Turabian jturabianf@hotmail.com <p>Cloperastine represents a special case on the list of drug repurposing potentially useful for treating COVID-19 in the early stages of the disease at the community or general practice level. Cloperastine is an antitussive drug marketed worldwide and especially by countries in North America, Europe, Japan, Brazil, Russia, India, China, South Africa, and Australia. The most common symptom of COVID-19 is cough. Therefore cloperastine already has the indication for its use in COVID-19. This supposes a comparative advantage over the rest of potentially useful reusable drugs for COVID-19, which may be indicated in comorbidities of the patient with COVID, but are not indicated for COVID-19 itself. Cloperastine is also a non-specific antiviral drug and has an action on the Sigma-1 receptor, which specifically resides in the endoplasmic reticulum membrane-associated with mitochondria. In addition, cloperastine is a type 1 sodium-dependent glucose cotransporter inhibitor, blocking glucose uptake in lung cells. A proposal is made to study the hypothesis of the potential effect of cloperastine in COVID-19, to assess the outcome of exposure to this drug (duration of symptoms, severity, hospitalization, viral load, etc.), in retrospective case-control studies and prospectively -and this possibility is a distinctive case of cloperastine compared to the rest of potentially useful drugs in the treatment of COVID-19-, through clinical trials, taking advantage of the special experiment of its authorized prescription from of the approved indication of cloperastine in the treatment of cough.</p> 2020-10-24T00:00:00-04:00 Copyright (c) 2020 International Research in Medical and Health Sciences https://irmhs.com/index.php/irmhs/article/view/42 Prosthodontic Rehabilitation of Flabby Ridge Using Two Different Impression Techniques- A Case Report 2020-11-08T12:12:59-05:00 Natasha Bathla natasha_nono999@yahoo.com Archana Nagpal natasha_nono999@yahoo.com Vishal Katna natasha_nono999@yahoo.com Komal Pathania natasha_nono999@yahoo.com <p>Flabby ridge is an excessive movable fibrous tissue, usually affecting the maxillary and mandibular edentulous ridges. It is a typical finding frequently observed in the maxillary anterior region. It usually occurs when natural teeth oppose an edentulous ridge or in long-term denture wearers. The management of flabby ridges includes surgical intervention, implant-retained prostheses, and conventional dentures fabricated using the modified impression technique. This case report depicts prosthodontic rehabilitation of patients with flabby ridges with two different impression modalities.</p> 2020-10-30T13:12:40-04:00 Copyright (c) 2020 International Research in Medical and Health Sciences